{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:30:21Z","timestamp":1786116621149,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma which is prone to high recurrence rate, and the fibrosarcomatous transformation of DFSP (FS-DFSP) is associated with a poorer prognosis and significant metastatic potential. Although the translocation of regions of chromosomes 17 and 22 that results in COL1A1-PDGFB fusion is generally acknowledged as a key genetic feature of DFSP, there is no established salvage treatment following resistance to imatinib, which targets the PDGFB pathway. In this study, we performed quantitative proteomics analyses of DFSP tumor tissues and paired adjacent normal skin, to uncover novel molecular mechanisms and potential therapeutic targets. Findings were validated using immunohistochemistry, Western Blot, Real-Time Quantitative PCR and cell viability assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pathway enrichment analysis including KEGG and GSEA revealed that spliceosome pathways and ECM-receptor interaction were associated with DFSP pathogenesis. The spliceosomal components SF3B, and SerpinB9, which is the endogenous inhibitor of granzyme B, were validated to be upregulated in tumor tissues. SerpinB9 was significantly overexpressed in the FS-DFSP subtype compared with the classic-type DFSP. Treatment with the SF3B1 inhibitor, Pladienolide-B, significantly reduced tumor cell viability. siRNA-mediated knockdown of SF3B1 and SF3B2, as well as Pladienolide-B treatment, inhibited\n                      <jats:italic>SERPINB9<\/jats:italic>\n                      expression without affecting pre-\n                      <jats:italic>SERPINB9<\/jats:italic>\n                      mRNA levels, suggesting splicing-dependent regulation. Additionally, quantitation of the tumor microenvironment cells using the MCP-counter algorithm indicated NK cells activation. The CD56 (NK cell surface marker), biomarkers of tumor-associated macrophage (TAM) such as CD14 and CD163, and transforming growth factor-\u03b2 induced (TGFBI) which is associated with TAM infiltration stained positive in DFSP tumors.\n                      <jats:italic>SERPINB9<\/jats:italic>\n                      mRNA expression showed a positive correlation with both NK cell abundance and FCGR3A (NK cell marker) mRNA level.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SerpinB9 overexpression is associated with fibrosarcomatous features in DFSP and may represent a candidate prognosis biomarker. The SF3B\/SERPINB9 axis is a potential therapeutic vulnerability, particularly in FS-DFSP. NK cell- and macrophage-related signatures were evident in DFSP tumor microenvironment, warranting further functional studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04458-4","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:36:39Z","timestamp":1782491799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteomics-based approach reveals the involvement of spliceosomal components SF3B and SerpinB9 in dermatofibrosarcoma protuberans"],"prefix":"10.1186","volume":"21","author":[{"given":"Yang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingshuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaojian","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-9026","authenticated-orcid":false,"given":"Yafeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"4","key":"4458_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/ced\/llac111","volume":"48","author":"SX Lim","year":"2023","unstructured":"Lim SX, Ramaiya A, Levell NJ, Venables ZC. Review of dermatofibrosarcoma protuberans. Clin Exp Dermatol. 2023;48(4):297\u2013302. https:\/\/doi.org\/10.1093\/ced\/llac111.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"4458_CR2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/DSS.0000000000004018","volume":"49","author":"DD Xiong","year":"2023","unstructured":"Xiong DD, Bordeaux JS. Incidence and survival Outcomes of dermatofibrosarcoma protuberans from 2000 to 2020: a Population-based Retrospective Cohort analysis. Dermatol Surg. 2023;49(12):1096\u2013103. https:\/\/doi.org\/10.1097\/DSS.0000000000004018.","journal-title":"Dermatol Surg"},{"issue":"4","key":"4458_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.det.2019.05.006","volume":"37","author":"A Allen","year":"2019","unstructured":"Allen A, Ahn C, Sangueza OP. Dermatofibrosarcoma Protuberans. Dermatol Clin. 2019;37(4):483\u201388. https:\/\/doi.org\/10.1016\/j.det.2019.05.006.","journal-title":"Dermatol Clin"},{"key":"4458_CR4","unstructured":"Menon G, Brooks J, Ml R. Dermatofibrosarcoma Protuberans. StatPearls: Treasure Isl (FL). 2024."},{"issue":"9","key":"4458_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/ijd.15497","volume":"60","author":"N Kibbi","year":"2021","unstructured":"Kibbi N, Wang D, Wang WL, Galan A, Leffell DJ, Christensen SR, et al. Dermatofibrosarcoma protuberans in pregnancy: a case series and review of the literature. Int J Dermatol. 2021;60(9):1114\u201319. https:\/\/doi.org\/10.1111\/ijd.15497.","journal-title":"Int J Dermatol"},{"issue":"6","key":"4458_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/bjd.20976","volume":"186","author":"C Peng","year":"2022","unstructured":"Peng C, Jian X, Xie Y, Li L, Ouyang J, Tang L, et al. Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing. Br J Dermatol. 2022;186(6):997\u20131009. https:\/\/doi.org\/10.1111\/bjd.20976.","journal-title":"Br J Dermatol"},{"issue":"4","key":"4458_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.suc.2022.05.004","volume":"102","author":"GA Vitiello","year":"2022","unstructured":"Vitiello GA, Lee AY, Berman RS. Dermatofibrosarcoma Protuberans: what is this? The Surg Clinics N Am. 2022;102(4):657\u201365. https:\/\/doi.org\/10.1016\/j.suc.2022.05.004.","journal-title":"The Surg Clinics N Am"},{"key":"4458_CR8","doi-asserted-by":"publisher","unstructured":"Bateman A, Martin M-J, Orchard S, Magrane M, Ahmad S, Alpi E, et al. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523\u201331. https:\/\/doi.org\/10.1093\/nar\/gkac1052.","DOI":"10.1093\/nar\/gkac1052"},{"issue":"5","key":"4458_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics: J Intgr Biol. 2012;16(5):284\u201387. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"Omics: J Intgr Biol"},{"issue":"6","key":"4458_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1074\/mcp.TIR119.001646","volume":"19","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Orre LM, Zhou Tran Y, Mermelekas G, Johansson HJ, Malyutina A, et al. DEqMS: a method for accurate variance estimation in differential protein expression analysis. Mol Cellular Proteomics. 2020;19(6):1047\u201357. https:\/\/doi.org\/10.1074\/mcp.TIR119.001646.","journal-title":"Mol Cellular Proteomics"},{"key":"4458_CR11","doi-asserted-by":"publisher","first-page":"926282","DOI":"10.3389\/fgene.2022.926282","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Sun D, Zheng H, Rao Y, Deng Y, Liang X, et al. Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans. Front Genet. 2022;13:926282. https:\/\/doi.org\/10.3389\/fgene.2022.926282.","journal-title":"Front Genet"},{"issue":"9","key":"4458_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/DSS.0000000000003853","volume":"49","author":"S Chen","year":"2023","unstructured":"Chen S, Xiong L, Zhao L, Li Y, Li L. Survival Outcomes and prognostic factors of Dermatofibrosarcoma Protuberans: a Population-based Retrospective Cohort analysis. Dermatol Surg. 2023;49(9):825\u201331. https:\/\/doi.org\/10.1097\/DSS.0000000000003853.","journal-title":"Dermatol Surg"},{"issue":"6","key":"4458_CR13","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1007\/s13577-023-00974-8","volume":"36","author":"JY Chan","year":"2023","unstructured":"Chan JY, Lee ECY, Li Z, Lee JY, Lim AH, Poon E. Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation. Hum Cell. 2023;36(6):2228\u201336. https:\/\/doi.org\/10.1007\/s13577-023-00974-8.","journal-title":"Hum Cell"},{"key":"4458_CR14","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2147\/OTT.S150235","volume":"11","author":"W Xiao","year":"2018","unstructured":"Xiao W, Que Y, Peng R, Ding Y, Zhao J, Wen X, et al. A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure. Onco Targets Ther. 2018;11:2439\u201343. https:\/\/doi.org\/10.2147\/OTT.S150235.","journal-title":"OTT"},{"issue":"2","key":"4458_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jid.2016.06.634","volume":"137","author":"M Tazzari","year":"2017","unstructured":"Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, et al. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. The J Invest Dermatol. 2017;137(2):484\u201393. https:\/\/doi.org\/10.1016\/j.jid.2016.06.634.","journal-title":"The J Invest Dermatol"},{"issue":"1","key":"4458_CR16","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1038\/s41598-023-29777-5","volume":"13","author":"A Samy","year":"2023","unstructured":"Samy A, Ozdemir MK, Alhajj R. Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research. Sci Rep. 2023;13(1):2704. https:\/\/doi.org\/10.1038\/s41598-023-29777-5.","journal-title":"Sci Rep"},{"issue":"1","key":"4458_CR17","doi-asserted-by":"publisher","first-page":"42504","DOI":"10.1038\/srep42504","volume":"7","author":"FF-L Chung","year":"2017","unstructured":"Chung FF-L, Tan PFTM, Raja VJ, Tan BS, Lim KH, Kam TS, et al. Jerantinine a induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1). Sci Rep. 2017;7(1):42504. https:\/\/doi.org\/10.1038\/srep42504.","journal-title":"Sci Rep"},{"issue":"1","key":"4458_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-020-00220-5","volume":"8","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Gong Q, Wang Y, Li M, Wang L, Ding H, et al. The biological function and clinical significance of SF3B1 mutations in cancer. Biomark Res. 2020;8(1):38. https:\/\/doi.org\/10.1186\/s40364-020-00220-5.","journal-title":"Biomark Res"},{"issue":"20","key":"4458_CR19","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-18-3965","volume":"79","author":"N Kawamura","year":"2019","unstructured":"Kawamura N, Nimura K, Saga K, Ishibashi A, Kitamura K, Nagano H, et al. SF3B2-mediated RNA splicing drives human prostate cancer progression. Cancer Res. 2019;79(20):5204\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3965.","journal-title":"Cancer Res"},{"key":"4458_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.trsl.2019.07.001","volume":"212","author":"JM Jimenez-Vacas","year":"2019","unstructured":"Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, et al. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Transl Res. 2019;212:89\u2013103. https:\/\/doi.org\/10.1016\/j.trsl.2019.07.001.","journal-title":"Transl Res"},{"issue":"5","key":"4458_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","volume":"94","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2016;94(5):509\u201322. https:\/\/doi.org\/10.1007\/s00109-015-1376-x.","journal-title":"J Mol Med (Berl)"},{"key":"4458_CR22","doi-asserted-by":"publisher","first-page":"1422113","DOI":"10.3389\/fimmu.2024.1422113","volume":"15","author":"H Huang","year":"2024","unstructured":"Huang H, Mu Y, Li S. The biological function of Serpinb9 and Serpinb9-based therapy. Front Immunol. 2024;15:1422113. https:\/\/doi.org\/10.3389\/fimmu.2024.1422113.","journal-title":"Front Immunol"},{"issue":"1","key":"4458_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00795-023-00374-9","volume":"57","author":"T Anami","year":"2024","unstructured":"Anami T, Ibe Y, Li L, Komohara Y, Hirao H, Harada M, et al. Overexpression of SerpinB9 in non-seminomatous germ cell tumors. Med Mol Morphol. 2024;57(1):68\u201375. https:\/\/doi.org\/10.1007\/s00795-023-00374-9.","journal-title":"Med Mol Morphol"},{"issue":"5","key":"4458_CR24","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.4049\/jimmunol.1300851","volume":"191","author":"J Azzi","year":"2013","unstructured":"Azzi J, Skartsis N, Mounayar M, Magee CN, Batal I, Ting C, et al. Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B\u2013producing regulatory T cells. J Immunol. 2013;191(5):2319\u201327. https:\/\/doi.org\/10.4049\/jimmunol.1300851.","journal-title":"J Immunol"},{"key":"4458_CR25","doi-asserted-by":"publisher","first-page":"216457","DOI":"10.1016\/j.canlet.2023.216457","volume":"578","author":"J Zhou","year":"2023","unstructured":"Zhou J, Lyu N, Wang Q, Yang M, Kimchi ET, Cheng K, et al. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Cancer Lett. 2023, Dec, 1;578:216457. https:\/\/doi.org\/10.1016\/j.canlet.2023.216457.","journal-title":"Cancer Lett"},{"issue":"9","key":"4458_CR26","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.7150\/thno.69605","volume":"12","author":"P Peng","year":"2022","unstructured":"Peng P, Zhu H, Liu D, Chen Z, Zhang X, Guo Z, et al. TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin \u03b1v\u03b25-src-Stat3 signaling. Theranostics. 2022, May, 16;12(9):4221\u201336. https:\/\/doi.org\/10.7150\/thno.69605.","journal-title":"Theranostics"},{"issue":"1","key":"4458_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13000-021-01123-1","volume":"16","author":"Y Chen","year":"2021","unstructured":"Chen Y, Shi YZ, Feng XH, Wang XT, He XL, Zhao M. Novel TNC-PDGFD fusion in fibrosarcomatous dermatofibrosarcoma protuberans: a case report. Diagn Pathol. 2021, Jul, 13;16(1):63. https:\/\/doi.org\/10.1186\/s13000-021-01123-1.","journal-title":"Diagn Pathol"},{"issue":"1","key":"4458_CR28","doi-asserted-by":"publisher","first-page":"2139074","DOI":"10.1080\/2162402X.2022.2139074","volume":"11","author":"S Ibanez-Molero","year":"2022","unstructured":"Ibanez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, et al. SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. Oncoimmunology. 2022;11(1):2139074. https:\/\/doi.org\/10.1080\/2162402X.2022.2139074.","journal-title":"Oncoimmunology"},{"issue":"5","key":"4458_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.cell.2020.10.045","volume":"183","author":"L Jiang","year":"2020","unstructured":"Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, et al. Direct tumor killing and immunotherapy through anti-SerpinB9 therapy. Cell. 2020;183(5):1219\u201333.e18. https:\/\/doi.org\/10.1016\/j.cell.2020.10.045.","journal-title":"Cell"},{"issue":"10","key":"4458_CR30","first-page":"3719","volume":"12","author":"B Zhou","year":"2019","unstructured":"Zhou B, Chen E, Chen J, Zhang J, Zhang N, Chen Z. Overexpression of proteinase inhibitor 9 is associated with poor prognosis in human hepatocellular carcinoma and with proliferation and apoptosis in HepG2 cells in vitro. Int J Clin Exp Pathol. 2019;12(10):3719\u201327.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"4458_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/gtc.12824","volume":"26","author":"K Matsumoto","year":"2021","unstructured":"Matsumoto K, Okamoto K, Okabe S, Fujii R, Ueda K, Ohashi K, et al. G-quadruplex-forming nucleic acids interact with splicing factor 3B subunit 2 and suppress innate immune gene expression. Genes Cells. 2021;26(2):65\u201382. https:\/\/doi.org\/10.1111\/gtc.12824.","journal-title":"Genes Cells"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04458-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:36:04Z","timestamp":1786016164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04458-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4458"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04458-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the protocol was approved by the Third Affiliated Hospital of Sun Yat-sen University Ethics Committee Board, People\u2019s Republic of China on 4th July 2018 ([2018]SC-02\u201306-01) and on 4th July 2022 ([2022]SC-02\u201306-01), and the study was performed in accordance with the Declaration of Helsinki (2024). The patients in this manuscript have given written informed consent to publication of their case details.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to the publication of this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"267"}}